Selected research highlights
The following journal publications, posters and presentations/discussions about fibrolamellar carcinoma and related topics have been recommended by our scientific advisors. Each of the listed scientific articles also includes a brief “plain English” overview that summarizes the results and implications of the published effort.
To view and search a complete listing of the nearly 600 articles published on fibrolamellar carcinoma since 1956, click here.
![](https://fibrofoundation.org/wp-content/smush-webp/2024/05/PLOS-Genetics-cover-03-24.jpg.webp)
DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinomaMarch 21, 2024    │    Ma, Tsai, Farghli, ..., Broom, Barrow & Sethupathy
![](https://fibrofoundation.org/wp-content/smush-webp/2024/05/cell-reports-medicine-cover-3-24.jpg.webp)
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinomaMarch 19, 2024    │    Kirk, Crawford, Chou, Guy, ..., Strome & Thomas
![](https://fibrofoundation.org/wp-content/smush-webp/2024/06/Scientific-reports-cover.jpg.webp)
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD‑1 and IL‑10 blockadeMarch 1, 2024    │    Daniel, Sullivan, Dickerson, ... , Riehle, Yeung, Carter, Barry & Pillarisetty
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/pediatric-blood-and-cancer-cover-sept-23.png.webp)
NCI intramural program approach to rare tumors: Natural history study of rare solid tumors in children and adults: A longitudinal, comprehensive data and biospecimen collection protocolJune 21, 2023    │    Wedekind, Reilly, Del Rivero, Lockridge, Allen, Raygada, Bernstein, Thomas, Vivelo, ... , Sandler & Widemann
![](https://fibrofoundation.org/wp-content/smush-webp/2023/09/science-advances-cover-6-23.jpg.webp)
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinomaJune 21, 2023    │    Levin, Tomasini, Knox, Shirani, ... & Simon
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/Nature-communications-cover-call.jpg.webp)
Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A lossMay 3, 2023    │    Rüland, Andreatta, Massalini, Chuva de Sousa Lopes, Clevers, Hendriks & Artegiani
![](https://fibrofoundation.org/wp-content/smush-webp/2023/09/npj-precision-oncology-cover.png.webp)
Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical dataMarch 23, 2023    │    Zack, Losert, Maisel, Wild, ... & Gordan
![](https://fibrofoundation.org/wp-content/smush-webp/2023/09/clinical-cancer-research-cover-1-23.jpg.webp)
Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACAJanuary 4, 2023    │    Neumayer, Ng, Jiang, Qureshi, ... & Simon
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/journal-for-immunotherapy-of-cancer-logo-cover.png.webp)
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumabDecember 9, 2022    │    Berger, Dinstag, Tirosh, Schiff, Kleiner, Aldape, Ruppin, Beker, Kurzrock
![](https://fibrofoundation.org/wp-content/smush-webp/2023/09/cancers-cover-11-22.jpg.webp)
Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint InhibitorsOctober 30, 2022    │    Chen, Popovic, Hsiehchen, Baretti, ... & Yarchoan
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/nature-communications-cover.png.webp)
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaOctober 27, 2022    │    Bauer, Kohler, Maringer, Bucher, Bilich, Zwich, Dicks, Nelde, ... & Walz
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/hepatology-communications-cover-12-22.jpg.webp)
Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based studyOctober 17, 2022    │    Berkovitz, Migler, Qureshi, Rosemore,Torbenson, Vaughan, Marcotte & Simon
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/hepatology-communications-cover-08-22.jpg.webp)
β-catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinomaSeptember 8, 2022    │    Gulati, Johnston, Rivas, Cast, ... , Shin & Timchenko
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/jci-insight-cover-08-22.jpg.webp)
Targeting BCL-XL in fibrolamellar hepatocellular carcinomaSeptember 8, 2022    │    Sheb, Ng, Lalazar, Rosemore, Finkelstein, ... & Simon
![](https://fibrofoundation.org/wp-content/smush-webp/2023/11/cancer-cover-7-22.jpg.webp)
Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative studyMay 13, 2022    │    Short, Kastenberg, Wei, Bondoc, Dasgupta, Tiao, Watters, Heaton, Lotakis, La Quaglia, ... , Utria, Meyers & Riehle
![](https://fibrofoundation.org/wp-content/smush-webp/2023/09/jci-insight-cover-06-22.jpg.webp)
Multi-omic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinomaApril 28, 2022    │    Francisco, … , Bardeesy & Sethupathy
![](https://fibrofoundation.org/wp-content/smush-webp/2023/09/nature-reviews-g-h-cover-05-22.jpg.webp)
A framework for fibrolamellar carcinoma research and clinical trialsFebruary 22, 2022    │    Dinh, Utria, Barry, Ma, Abou- Alfa, Gordan, Jaffee, Scott, Zucman- Rossi, O’Neill, Furth & Sethupathy
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/plos-one-cover.png.webp)
DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signalingFebruary 15, 2022    │    Kim, Kycia, Karski, Ma, Bordt, Kwan, ..., Sethupathy, & Vakili
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/cancer-discovery-cover-10-21.jpg.webp)
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient ScreeningOctober 1, 2021    │    Lalazar, Requena, ... & Simon
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/Current-problems-in-cancer-cover-150.jpg.webp)
Fibrolamellar carcinoma: An entity all its ownJuly 18, 2021    │    O'Neill, Church, Perez-Atayde, ... & Vakili
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/gut-cover-11-20.png.webp)
Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinomaFebruary 12, 2020    │    De Toni & Roessler
![](https://fibrofoundation.org/wp-content/smush-webp/2023/09/anticancer-research-cover.jpg.webp)
Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer DatabaseFebruary 5, 2020    │    Assi, Mukherjee, Machiorlatti, Vesely, Pareek & Hatoum
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/eLife-cover-19.jpg.webp)
An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinomaMay 7, 2019    │    Turnham, Smith, Kenerson, Omar, Golkowski, Garcia, Bauer, Lau, Sullivan, ..., Yeung & Scott
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/CMGH-cover-2-19-150.jpg.webp)
MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar CarcinomaFebruary 11, 2019    │    Dinh, Jewell, ... & Sethupathy
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/dovepress-logo-150.jpg.webp)
Road map for fibrolamellar carcinoma: progress and goals of a diversified approachJanuary 31, 2019    │    Kastenhuber, Craig, ... & Abou-Alfa
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/gastroenterology-cover-150.jpg.webp)
CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates that the DNAJB1-PRKACA Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular CarcinomaDecember 1, 2017    │    Engelholm, Riaz, ... & Frödin
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/Modern-pathology-jan-18-cover.jpg.webp)
Molecular testing for the clinical diagnosis of fibrolamellar carcinomaSeptember 1, 2017    │    Graham, Yeh, Lam-Himlin, Roberts, Terracciano, Cruise, Greipp, ... , & Torbenson
![](https://fibrofoundation.org/wp-content/smush-webp/2023/10/nature-communications-cover-2.jpg.webp)
Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cellsOctober 6, 2015    │    Oikawa, Wauthier, Dinh, Selitsky, Reyna-Neyra, ... , Sethupathy & Reid
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/oncotarget-cover-150.jpg.webp)
The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patientsDecember 1, 2014    │    Darcy, Chiaroni-Clarke, ... & Simon
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/science-cover-feb-14-150.jpg.webp)
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinomaFebruary 28, 2014    │    Honeyman, Simon, ... & Simon
![](https://fibrofoundation.org/wp-content/smush-webp/2023/11/JHU-SITC-2023.png.webp)
A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinomaNovember 1, 2023    │    Baretti, Ladle, Nauroth, Wang, Durham, Thoburn, Ferguson, Thompson, ... , Jaffee & Yarchoan
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/gemox-len-poster-image-150.png.webp)
Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 PatientsMay 1, 2021    │    Reid Davison, Paul Kent
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/promise-of-immunotherapy-150.jpg.webp)
Seeking a Cure: The Promise of ImmunotherapyJune 24, 2021    │    Elizabeth Jaffee, Paul Thomas & Mark Furth
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/kent-grand-rounds-150.jpg.webp)
Fibrolamellar Carcinoma New Hope for a Terrible Cancer of Young PeopleApril 7, 2021    │    Paul Kent, MD
![](https://fibrofoundation.org/wp-content/smush-webp/2021/07/diagnosing-flc-graham-150.jpg.webp)